WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has recently submitted a grant application to the Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs. If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure (MCM) against bio-terrorism and emerging infectious diseases such as Ebola/Marburg, and Dengue.
